• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去氨加压素口服冻干制剂在生长猪仔中的群体药代动力学建模:以儿科人群为模型

Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population.

作者信息

Gasthuys Elke, Vermeulen An, Croubels Siska, Millecam Joske, Schauvliege Stijn, van Bergen Thomas, De Bruyne Pauline, Vande Walle Johan, Devreese Mathias

机构信息

Department of Pharmacology, Toxicology and Biochemistry, Ghent University, Merelbeke, Belgium.

Department of Bio-analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.

出版信息

Front Pharmacol. 2018 Jan 31;9:41. doi: 10.3389/fphar.2018.00041. eCollection 2018.

DOI:10.3389/fphar.2018.00041
PMID:29445339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5797931/
Abstract

Desmopressin is used to treat primary nocturnal enuresis in children. Over the years, various formulations of desmopressin were commercialized of which the sublingual melt tablet is preferred in the pediatric population, despite the lack of full PK studies in this population. A full PK study was performed in growing conventional piglets to evaluate if this juvenile animal model can provide supplementary information to complement the information gap in the pediatric population. A desmopressin sublingual melt tablet (120 μg) was administered to 32 male piglets aged 8 days, 4 weeks, 7 weeks, and 6 months (each group = 8). Population PK (pop-PK) analysis was performed to derive the PK parameters, the between- and within-subject variabilities and the effects of covariates. Desmopressin demonstrated two-compartmental PK, with a dual, sequential absorption process, and linear elimination. Body weight was the only significant covariate on clearance and on apparent volume of distribution of the central compartment. In human pediatric trials, no double peak in the absorption phase was observed in the plasma concentration-time curves, possibly due to the sparse sampling strategy applied in those pediatric studies. Therefore, it is recommended to perform additional studies, based on the sampling protocol applied in the current study.

摘要

去氨加压素用于治疗儿童原发性夜间遗尿症。多年来,多种去氨加压素制剂已商业化,其中舌下溶片在儿科人群中更受青睐,尽管该人群缺乏完整的药代动力学(PK)研究。在生长中的普通仔猪中进行了一项完整的PK研究,以评估这种幼年动物模型是否可以提供补充信息,以弥补儿科人群中的信息空白。将一片去氨加压素舌下溶片(120μg)给予32只8日龄、4周龄、7周龄和6月龄的雄性仔猪(每组 = 8只)。进行群体药代动力学(pop-PK)分析以得出PK参数、受试者间和受试者内变异性以及协变量的影响。去氨加压素表现出二室PK,具有双重、顺序吸收过程和线性消除。体重是清除率和中央室表观分布容积的唯一显著协变量。在儿科人体试验中,血浆浓度-时间曲线的吸收相中未观察到双峰,这可能是由于这些儿科研究中采用的稀疏采样策略所致。因此,建议根据本研究中应用的采样方案进行额外的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/3374b79a81af/fphar-09-00041-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/af7137062f6a/fphar-09-00041-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/96685d2ae2e2/fphar-09-00041-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/3a8f597521fe/fphar-09-00041-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/70380ff5e7b2/fphar-09-00041-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/3374b79a81af/fphar-09-00041-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/af7137062f6a/fphar-09-00041-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/96685d2ae2e2/fphar-09-00041-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/3a8f597521fe/fphar-09-00041-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/70380ff5e7b2/fphar-09-00041-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b8c/5797931/3374b79a81af/fphar-09-00041-g0005.jpg

相似文献

1
Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population.去氨加压素口服冻干制剂在生长猪仔中的群体药代动力学建模:以儿科人群为模型
Front Pharmacol. 2018 Jan 31;9:41. doi: 10.3389/fphar.2018.00041. eCollection 2018.
2
Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis.去氨加压素片剂和口服冻干制剂在单症状性夜间遗尿症儿童中的药代动力学。
Eur J Pediatr. 2014 Feb;173(2):223-8. doi: 10.1007/s00431-013-2108-2. Epub 2013 Aug 30.
3
Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.在儿童中声称去氨加压素治疗等效性需要儿科数据:一项群体药代动力学-药效学分析。
Eur J Clin Pharmacol. 2018 Mar;74(3):297-305. doi: 10.1007/s00228-017-2386-0. Epub 2017 Dec 3.
4
A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis.口服去氨加压素冻干制剂(MELT)与片剂剂型治疗儿童及青少年原发性夜间遗尿症的随机对照研究
Int J Clin Pract. 2007 Sep;61(9):1454-60. doi: 10.1111/j.1742-1241.2007.01493.x. Epub 2007 Jul 26.
5
Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review.小儿遗尿症患儿去氨加压素的儿科药理学:全面综述。
Paediatr Drugs. 2020 Aug;22(4):369-383. doi: 10.1007/s40272-020-00401-7.
6
Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.食物和药物制剂对去氨加压素在儿童体内药代动力学的影响。
Clin Pharmacokinet. 2016 Sep;55(9):1159-70. doi: 10.1007/s40262-016-0393-4.
7
[Comparison of two sublingual types of desmopressin in 6-year-old and more children with primary nocturnal enuresis. About an international randomized cross-over study].[两种舌下含服去氨加压素剂型在6岁及以上原发性夜间遗尿症儿童中的比较。一项国际随机交叉研究]
Prog Urol. 2009 Feb;19(2):132-8. doi: 10.1016/j.purol.2008.09.061. Epub 2009 Jan 8.
8
Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues.去氨加压素在单纯性夜间遗尿症儿童中的应用是否仍有必要?:关注安全性问题。
Drug Saf. 2010 Apr 1;33(4):261-71. doi: 10.2165/11319110-000000000-00000.
9
Increased renal concentrating ability after long-term oral desmopressin lyophilisate treatment contributes to continued success for monosymptomatic nocturnal enuresis.长期口服去氨加压素冻干物治疗后肾脏浓缩能力增强,有助于单症状性夜间遗尿症持续取得疗效。
Int J Urol. 2017 Sep;24(9):698-702. doi: 10.1111/iju.13394. Epub 2017 Jun 21.
10
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.去氨加压素口服冻干剂型在原发性夜间遗尿症儿童和健康成人中的药代动力学。
J Clin Pharmacol. 2006 Oct;46(10):1204-11. doi: 10.1177/0091270006291838.

引用本文的文献

1
Comparative Diagnostic Performance of Copeptin After Hypertonic Saline Infusion Versus Water Deprivation Test in Pediatric Patients with Polyuria-Polydipsia Syndrome.高渗盐水输注后copeptin与禁水试验在小儿多尿-多饮综合征患者中的比较诊断性能
Int J Mol Sci. 2025 Jun 6;26(12):5449. doi: 10.3390/ijms26125449.
2
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.蛋白类和肽类药物的现行与有前景的口服递药方法。
Int J Mol Sci. 2024 Jan 9;25(2):815. doi: 10.3390/ijms25020815.
3
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders.

本文引用的文献

1
Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.在儿童中声称去氨加压素治疗等效性需要儿科数据:一项群体药代动力学-药效学分析。
Eur J Clin Pharmacol. 2018 Mar;74(3):297-305. doi: 10.1007/s00228-017-2386-0. Epub 2017 Dec 3.
2
Postnatal Maturation of the Glomerular Filtration Rate in Conventional Growing Piglets As Potential Juvenile Animal Model for Preclinical Pharmaceutical Research.传统生长仔猪肾小球滤过率的产后成熟:作为临床前药物研究潜在幼年动物模型
Front Pharmacol. 2017 Jun 29;8:431. doi: 10.3389/fphar.2017.00431. eCollection 2017.
3
Repetitive urine and blood sampling in neonatal and weaned piglets for pharmacokinetic and pharmacodynamic modelling in drug discovery: a pilot study.
去氨加压素在出血性疾病中的止血和节血作用。
Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12.
4
Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.健康受试者和长链脂肪酸氧化障碍患者用三庚酸治疗后的庚酸群体药代动力学。
Clin Pharmacol Drug Dev. 2022 Nov;11(11):1264-1272. doi: 10.1002/cpdd.1145. Epub 2022 Jul 31.
5
The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development.儿科药物研发中的新生和幼年猪
Pharmaceutics. 2020 Dec 30;13(1):44. doi: 10.3390/pharmaceutics13010044.
6
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors.使用包含表观遗传调节剂和免疫检查点抑制剂的定量系统药理学模型在HER2阴性乳腺癌中进行虚拟临床试验。
Front Bioeng Biotechnol. 2020 Feb 25;8:141. doi: 10.3389/fbioe.2020.00141. eCollection 2020.
7
An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?儿童人群 dDAVP 的综合药代动力学/药效学分析:PK 差异如何转化为临床结局?
Clin Pharmacokinet. 2020 Jan;59(1):81-96. doi: 10.1007/s40262-019-00798-6.
8
Metabolism of Ibuprofen in Growing Conventional Pigs: A Pharmacokinetic Approach.布洛芬在生长中的普通猪体内的代谢:一种药代动力学方法。
Front Pharmacol. 2019 Jun 27;10:712. doi: 10.3389/fphar.2019.00712. eCollection 2019.
9
Developmental Pharmacokinetics and Safety of Ibuprofen and Its Enantiomers in the Conventional Pig as Potential Pediatric Animal Model.布洛芬及其对映体在作为潜在儿科动物模型的普通猪中的发育药代动力学和安全性
Front Pharmacol. 2019 May 9;10:505. doi: 10.3389/fphar.2019.00505. eCollection 2019.
在新生仔猪和断奶仔猪中进行重复尿液和血液采样以用于药物发现中的药代动力学和药效学建模:一项初步研究。
Lab Anim. 2017 Oct;51(5):498-508. doi: 10.1177/0023677217692372. Epub 2017 Feb 8.
4
Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.食物和药物制剂对去氨加压素在儿童体内药代动力学的影响。
Clin Pharmacokinet. 2016 Sep;55(9):1159-70. doi: 10.1007/s40262-016-0393-4.
5
The Potential Use of Piglets as Human Pediatric Surrogate for Preclinical Pharmacokinetic and Pharmacodynamic Drug Testing.仔猪作为人类儿科替代物用于临床前药代动力学和药效学药物测试的潜在用途。
Curr Pharm Des. 2016;22(26):4069-85. doi: 10.2174/1381612822666160303111031.
6
Experimental design and analysis and their reporting: new guidance for publication in BJP.实验设计与分析及其报告:发表于《英国药理学杂志》的新指南
Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856.
7
Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis.去氨加压素片剂和口服冻干制剂在单症状性夜间遗尿症儿童中的药代动力学。
Eur J Pediatr. 2014 Feb;173(2):223-8. doi: 10.1007/s00431-013-2108-2. Epub 2013 Aug 30.
8
Clinical study shows improved absorption of desmopressin with novel formulation.
Pharm Res. 2009 Jul;26(7):1618-25. doi: 10.1007/s11095-009-9871-9. Epub 2009 Mar 19.
9
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.去氨加压素口服冻干剂型在原发性夜间遗尿症儿童和健康成人中的药代动力学。
J Clin Pharmacol. 2006 Oct;46(10):1204-11. doi: 10.1177/0091270006291838.
10
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.健康受试者和肾功能受损患者静脉注射去氨加压素后的药代动力学和肾排泄情况。
Br J Clin Pharmacol. 2004 Oct;58(4):352-8. doi: 10.1111/j.1365-2125.2004.02175.x.